BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 31303270)

  • 1. Fidelity of a PDX-CR model for bladder cancer.
    Mondal AM; Ma AH; Li G; Krawczyk E; Yuan R; Lu J; Schlegel R; Stamatakis L; Kowalczyk KJ; Philips GK; Pan CX; Liu X
    Biochem Biophys Res Commun; 2019 Sep; 517(1):49-56. PubMed ID: 31303270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-Derived Xenograft Models for Translational Prostate Cancer Research and Drug Development.
    Philp LK
    Methods Mol Biol; 2024; 2806():153-185. PubMed ID: 38676802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.
    Pan CX; Zhang H; Tepper CG; Lin TY; Davis RR; Keck J; Ghosh PM; Gill P; Airhart S; Bult C; Gandara DR; Liu E; de Vere White RW
    PLoS One; 2015; 10(8):e0134346. PubMed ID: 26270481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conditional Reprogramming Modeling of Bladder Cancer for Clinical Translation.
    Daneshdoust D; Yin M; Luo M; Sundi D; Dang Y; Lee C; Li J; Liu X
    Cells; 2023 Jun; 12(13):. PubMed ID: 37443748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of stable PDX derived cell lines using conditional reprogramming.
    Borodovsky A; McQuiston TJ; Stetson D; Ahmed A; Whitston D; Zhang J; Grondine M; Lawson D; Challberg SS; Zinda M; Pollok BA; Dougherty BA; D'Cruz CM
    Mol Cancer; 2017 Dec; 16(1):177. PubMed ID: 29212548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis.
    Wang J; Xing B; Liu W; Li J; Wang X; Li J; Yang J; Ji C; Li Z; Dong B; Gao J; Shen L
    Theranostics; 2019; 9(12):3485-3500. PubMed ID: 31281492
    [No Abstract]   [Full Text] [Related]  

  • 7. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development.
    Palanisamy N; Yang J; Shepherd PDA; Li-Ning-Tapia EM; Labanca E; Manyam GC; Ravoori MK; Kundra V; Araujo JC; Efstathiou E; Pisters LL; Wan X; Wang X; Vazquez ES; Aparicio AM; Carskadon SL; Tomlins SA; Kunju LP; Chinnaiyan AM; Broom BM; Logothetis CJ; Troncoso P; Navone NM
    Clin Cancer Res; 2020 Sep; 26(18):4933-4946. PubMed ID: 32576626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.
    Jäger W; Xue H; Hayashi T; Janssen C; Awrey S; Wyatt AW; Anderson S; Moskalev I; Haegert A; Alshalalfa M; Erho N; Davicioni E; Fazli L; Li E; Collins C; Wang Y; Black PC
    Oncotarget; 2015 Aug; 6(25):21522-32. PubMed ID: 26041878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
    Kang HN; Choi JW; Shim HS; Kim J; Kim DJ; Lee CY; Hong MH; Park SY; Park AY; Shin EJ; Lee SY; Pyo KH; Yun MR; Choi HM; Lee SS; Kim SY; Lee H; Paik S; Cho BC; Lee JG; Kim HR
    Lung Cancer; 2018 Oct; 124():168-178. PubMed ID: 30268457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells.
    Gheibi P; Zeng S; Son KJ; Vu T; Ma AH; Dall'Era MA; Yap SA; de Vere White RW; Pan CX; Revzin A
    Sci Rep; 2017 Sep; 7(1):12277. PubMed ID: 28947782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical models for bladder cancer therapy research.
    Ertl I; Shariat SF; Berger W; Englinger B
    Curr Opin Urol; 2024 Jul; 34(4):244-250. PubMed ID: 38630912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-Derived Bladder Cancer Xenografts.
    Bernardo C; Santos LL
    Methods Mol Biol; 2018; 1655():169-175. PubMed ID: 28889386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer.
    Cirone P; Andresen CJ; Eswaraka JR; Lappin PB; Bagi CM
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):525-38. PubMed ID: 24442130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-derived xenografts as in vivo models for research in urological malignancies.
    Inoue T; Terada N; Kobayashi T; Ogawa O
    Nat Rev Urol; 2017 May; 14(5):267-283. PubMed ID: 28248952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling of Patient-Derived Xenografts in Colorectal Cancer.
    Katsiampoura A; Raghav K; Jiang ZQ; Menter DG; Varkaris A; Morelli MP; Manuel S; Wu J; Sorokin AV; Rizi BS; Bristow C; Tian F; Airhart S; Cheng M; Broom BM; Morris J; Overman MJ; Powis G; Kopetz S
    Mol Cancer Ther; 2017 Jul; 16(7):1435-1442. PubMed ID: 28468778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies.
    Heo EJ; Cho YJ; Cho WC; Hong JE; Jeon HK; Oh DY; Choi YL; Song SY; Choi JJ; Bae DS; Lee YY; Choi CH; Kim TJ; Park WY; Kim BG; Lee JW
    Cancer Res Treat; 2017 Oct; 49(4):915-926. PubMed ID: 28052650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-Derived Xenografts: A Valuable Preclinical Model for Drug Development and Biomarker Discovery.
    Weng T; Jenkins BJ; Saad MI
    Methods Mol Biol; 2024; 2806():19-30. PubMed ID: 38676793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.
    Drapkin BJ; George J; Christensen CL; Mino-Kenudson M; Dries R; Sundaresan T; Phat S; Myers DT; Zhong J; Igo P; Hazar-Rethinam MH; Licausi JA; Gomez-Caraballo M; Kem M; Jani KN; Azimi R; Abedpour N; Menon R; Lakis S; Heist RS; Büttner R; Haas S; Sequist LV; Shaw AT; Wong KK; Hata AN; Toner M; Maheswaran S; Haber DA; Peifer M; Dyson N; Thomas RK; Farago AF
    Cancer Discov; 2018 May; 8(5):600-615. PubMed ID: 29483136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.
    Wei L; Chintala S; Ciamporcero E; Ramakrishnan S; Elbanna M; Wang J; Hu Q; Glenn ST; Murakami M; Liu L; Gomez EC; Sun Y; Conroy J; Miles KM; Malathi K; Ramaiah S; Anbarasu A; Woloszynska-Read A; Johnson CS; Conroy J; Liu S; Morrison CD; Pili R
    Oncotarget; 2016 Nov; 7(47):76374-76389. PubMed ID: 27823983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-Derived Xenograft Models in Cancer Research: Methodology, Applications, and Future Prospects.
    Aslani S; Saad MI
    Methods Mol Biol; 2024; 2806():9-18. PubMed ID: 38676792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.